Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247AM3)(COMPLETED) - Full Text View

Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247AM3)(COMPLETED)

This study has been completed.

Sponsored by:	Schering-Plough
Information provided by:	Schering-Plough
ClinicalTrials.gov Identifier:	NCT00076856

Purpose

The purpose of this study is to demonstrate improvement in overall survival for the combination of whole brain radiation therapy (WBRT) plus temozolomide (TMZ) versus WBRT alone. Secondary objective is to demonstrate an improvement in the time to radiological CNS progression with the addition of TMZ to WBRT.

Condition	Intervention	Phase
Carcinoma, Non-Small-Cell Lung Neoplasm Metastasis Brain Neoplasms	Drug: Temozolomide	Phase II

MedlinePlus related topics:

Brain Cancer Cancer Lung Cancer

Drug Information available for:

Temozolomide

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Efficacy Study

Official Title:	A Randomized, Open-Label Phase 2 Study of Temozolomide Added to Whole Brain Radiation Therapy Versus Whole Brain Radiation Therapy Alone for the Treatment of Brain Metastasis From Non-Small Cell Lung Cancer

Further study details as provided by Schering-Plough:

Primary Outcome Measures:

Overall Survival

Secondary Outcome Measures:

Time to radiological CNS progression

Estimated Enrollment:	100
Study Start Date:	March 2004
Estimated Study Completion Date:	November 2007

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Age greater than or equal to 18
Histologically or cytologically confirmed non-small-cell lung cancer (NSCLC)
At least one brain metastasis diagnosed within 30 days of randomization
Brain metastases must not have been previously treated with WBRT or radiosurgery
No more than 2 sites of extracranial metastases
May have received prior radiation therapy to the primary tumor and/or systemic metastatic sites
Meets protocol requirements for specified laboratory values.
Written informed consent and cooperation of patient
Appropriate use of effective contraception if of childbearing potential.
Karnofsky Performance Status KPS greater than 70
Score less than 2 on all criteria of the Comprehensive Neurological Outcome Scale (CNOS)

Contacts and Locations

No Contacts or Locations Provided

More Information

Study ID Numbers:	P03247
First Received:	February 4, 2004
Last Updated:	March 1, 2007
ClinicalTrials.gov Identifier:	NCT00076856
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Thoracic Neoplasms

Non-small cell lung cancer

Central Nervous System Diseases

Central Nervous System Neoplasms

Brain Diseases

Temozolomide

Carcinoma

Brain Neoplasms

Respiratory Tract Diseases

Lung Neoplasms

Lung Diseases

Neoplasm Metastasis

Carcinoma, Non-Small-Cell Lung

Nervous System Neoplasms

Neoplasms, Glandular and Epithelial

Additional relevant MeSH terms:

Respiratory Tract Neoplasms

Neoplasms by Histologic Type

Molecular Mechanisms of Pharmacological Action

Antineoplastic Agents

Nervous System Diseases

Pharmacologic Actions

Neoplasms

Neoplastic Processes

Neoplasms by Site

Pathologic Processes

Therapeutic Uses

Antineoplastic Agents, Alkylating

Alkylating Agents

ClinicalTrials.gov processed this record on November 19, 2008